Abstract
Purpose :
Plasma rich in growth factors (PRGF) is a novel autologous ophthalmic therapy that contains a large number of biologically active agents that promote tissue regeneration, healing modulation and anti-inflammatory properties, among others. PRGF can be used in diverse formulations and has been tested in some cases of macular hole improving anatomic and visual outcomes. However, the molecular mechanisms of PRGF in the macular treatment is not fully understood. Here, we showed a preliminary study of modulation response of PRGF in a macular hole in vivo model.
Methods :
A retinal break in the macula area were performed in New Zealand rabbits with an ACCURUS® Surgical System. At day 7 eyes were treated by injection of saline or PRGF in the macula hole. Electroretinography (ERG) measurements was performed at month of study. After sacrifice, eyes were collected and the sections were analyzed to IL1b, IL6, IL18, MCP1, proliferation and cell death markers.
Results :
PRGF reduced cell death in the area around the damage without proliferation detection. The integrity of the retinal structure was better in PRGF-treated eyes. The glial cell response to damage was maintained and no significant differences were observed with PRGF treatment. There was an inflammatory response at the injury area detected by activation of IL1b, IL6 and MCP1. PRGF treatment reduced the expression of these markers. In addition, a reduction of IL18 was observed with respect to uninjured eyes, suggesting a possible activation of autophagy, as previously described.
Conclusions :
The use of PRGF could be used as therapy in the surgical repair of macular holes reducing inflammation and maintaining the functionality of cells.
This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.